Peter Coleman
Peter has over 20 years CDMO ATMP Executive experience and is now leading the UK company through a period of dynamic evolution and innovation, driven by RoslinCT’s mission to save patient lives globally.
Peter joined RoslinCT in March 2022, prior to that he was the CEO of Cobra Biologics, a position he held from 2011 to Mar 2021 up to when the business was sold overseeing multiple acquisitions and fundraising activities.
He has over 20 years of ATMP CDMO experience as both CFO and CEO and he is a qualified accountant with an MBA from Manchester Business School. During his tenure as CEO of Cobra, he oversaw rapid growth in both revenue and EBITDA as the business focused on Advanced Therapies.
Peter has been an active member of the UK life science infrastructure as a member of the MMIP. He is also a multiple award winner, with the Queen’s Award for Enterprise in 2018 and joint winner of the BIA Richard Wilson Impact Award in 2020 for his involvement in the BIA’s UK COVID Vaccine Taskforce.
